Clinical Trial

BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President

ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and…

1 year ago

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024

-  Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- -  Review of recently…

1 year ago

Mainz Biomed Provides Year-End Corporate Review 2023

European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced…

1 year ago

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a…

1 year ago

Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity…

1 year ago

Tivic Health Announces Launch of New and Improved ClearUP 2.0

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic”) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine,…

1 year ago

Accenture Invests in QuantHealth to Accelerate Use of AI-powered Clinical Trial Simulations to Drive Cost-Effective Drug Development

NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Accenture (NYSE: ACN) announced it has made a strategic investment, through Accenture Ventures, in…

1 year ago

Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)

KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage…

1 year ago

Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference

Company announces product sales for 2023 of approximately $6.7 billion (unaudited); U.S. COVID-19 market share season to date increased to…

1 year ago

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in…

1 year ago